Anne-Catherine Gérard

Anne-Catherine Gérard

Auto-generated profile, based on publicly available information

Anne-Catherine Gérard

Pole of Experimental Morphology, Institute of Experimental and Clinical Research (IREC), Catholic University of Louvain (UCL), Brussels, Belgium and Department of Endocrinology and Diabetology, Regional Hospital Center (CHR) Mons-Hainaut, Belgium and Institute of life sciences (ISV), Catholic University of Louvain (UCL), Belgium

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in The American Journal of Pathology
Verified
Journal Article
Closed access
SPSylvie Poncin
Sylvie Poncin
SESandrine Van Eeckoudt
Sandrine Van Eeckoudt
KHKevin Humblet
Kevin Humblet
ICIdes M. Colin
Ides M. Colin
AGAnne-Catherine Gérard
Anne-Catherine Gérard

1 December 2011 in Thyroid®
Verified
Journal Article
Closed access
CGCaroline Geers
Caroline Geers
ICIdes M. Colin
Ides M. Colin
AGAnne-Catherine Gérard
Anne-Catherine Gérard
Background: Angiogenesis plays an essential role in embryonic and tumoral developments. Vascular endothelial growth factor (VEGF), one of the best known proangiogenic factors, is increased in thyroid cancers, especially in papillary carcinomas (PC). However, other regulating mechanisms refine VEGF-induced cellular changes, such as the Notch family of ligands and receptors. Their role has not yet been investigated in the thyroid. The purpose of our study was to analyze the expression of Notch1, Notch4, and Delta-like 4 (DLL4) in benign and malignant thyroid lesions. Methods: The expression of Notch1, Notch4, and DLL4 was analyzed by immunohistochemistry, quantitative reverse transcriptase–polymerase chain reaction (qRT-PCR), and Western-blot in normal thyroids (NTs), hyperplasic thyroids from patients with Graves' disease (GD), microcarcinomas, PC, and follicular carcinomas. Results: The immunohistochemical expression of Notch1, Notch4, and DLL4 was highly variable in thyrocytes from NTs and GD. In contrast, the staining in tumors was homogeneous and often intense. The increased expression of Notch1, Notch4, and DLL4 in carcinomas compared with the neighboring normal tissue was confirmed by qRT-PCR and Western-blot. However, only capillary endothelial cells from GD samples were positive for DLL4, the expression being restricted to large vessels in carcinomas and NTs. Conclusions: The detection of Notch1, Notch4, and DLL4 in thyrocytes and their regulation in various pathologies suggest that this pathway may play a role in thyroid carcinogenesis and angiogenesis.

1 June 2009 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
AGAnne-Catherine Gérard
Anne-Catherine Gérard
SPSylvie Poncin
Sylvie Poncin
JAJean-Nicolas Audinot
Jean-Nicolas Audinot
JDJean-François Denef
Jean-François Denef
ICIdes M. Colin
Ides M. Colin
Vascular supply is an obvious requirement for all organs. In addition to oxygen and nutrients, blood flow also transports essential trace elements. Iodine, which is a key element in thyroid hormone synthesis, is one of them. An inverse relationship exists between the expansion of the thyroid microvasculature and the local availability of iodine. This microvascular trace element-dependent regulation is unique and contributes to keep steady the iodide delivery to the thyroid. Signals involved in this regulation, such as VEGF-A, originate from thyrocytes as early TSH-independent responses to iodide scarcity. The question raised in this paper is how thyrocytes, facing an acute drop in intracellular stores of iodine, generate angiogenic signals acting on adjacent capillaries. Using in vitro models of rat and human thyroid cells, we show for the first time that the deficit in iodine is related to the release of VEGF-A via a reactive oxygen species/hypoxia-inducible factor-1-dependent pathway.

1 July 2012 in Thyroid®
Verified
Journal Article
Closed access
AGAnne-Catherine Gérard
Anne-Catherine Gérard
KHKevin Humblet
Kevin Humblet
CWCindy Wilvers
Cindy Wilvers
SPSylvie Poncin
Sylvie Poncin
HDHanane Derradji
Hanane Derradji
ICIdes M. Colin
Ides M. Colin
Background: In the thyroid, iodine deficiency (ID) induces angiogenesis via a tightly controlled reactive oxygen species (ROS)–hypoxia inducible factor-1 (HIF-1)–vascular endothelial growth factor (VEGF) dependent pathway (ROS-HIF-VEGF). Deficient iodine intake may be associated with increased thyroid cancer incidence. The hypothesis of this work is to test whether ID affects the angiogenic processes in thyroid malignant cells by altering the ROS-HIF-VEGF pathway. Methods: Goiters were obtained in RET/PTC3 transgenic and wild-type (wt) mice and ID was induced in three thyroid carcinoma cell lines (TPC-1, 8305c, and R082-w1). Thyroid blood flow, VEGF mRNA and protein, and HIF-1α protein expression were measured. The role of HIF-1 and of ROS was assessed using echinomycin and N-acetylcysteine (NAC), respectively. Results: The goitrogen treatment increased the thyroid blood flow in wt and RET/PTC3 mice. Compared with wt mice, basal VEGF expression was higher in RET/PTC3 mice and increased with goitrogen treatment. In the three cell lines, ID induced marked increases in VEGF mRNA, and moderate increases in HIF-1α protein expression that were not transient as in normal cells. ID-induced VEGF mRNA expression was fully (8305c), partially (TPC-1), or not (R082-w1) blocked by echinomycin. NAC had no effect on ID-induced VEGF mRNA and HIF-1α protein expression in the three cell lines. Conclusions: ID induces a long lasting angiogenic phenotype in thyroid cancer cells that occurs through VEGF induction via a pathway partially mediated by HIF-1, but not by ROS. These results suggest that, in contrast with normal cells, ID-induced angiogenesis in cancer cells occurs via alternative and likely less controlled routes, thereby leading to uncontrolled growth.

1 June 2016
Verified
Journal Article
Closed access
JVJessica Vanderstraeten
Jessica Vanderstraeten
HDHanane Derradji
Hanane Derradji
JCJulie Craps
Julie Craps
Pierre SonveauxPierre Sonveaux
Pierre Sonveaux
ICIdes M Colin
Ides M Colin
AGAnne-Catherine Gérard
Anne-Catherine Gérard

1 March 2017 in Diabetes & Metabolism
Verified
Journal Article
Closed access
IPIsabelle Paris
Isabelle Paris
CHCorinne Henry
Corinne Henry
AGAnne Catherine Gérard
Anne Catherine Gérard
FPFrançoise Pirard
Françoise Pirard
ICIdes Colin
Ides Colin